Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome (II), Fluorouracil + Bevacizumab/Cetuximab in Advanced Colorectal Cancer
NCT06540326Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of irinotecan liposome in colorectal cancer (CRC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate at 1 year. Started Nov 2024; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06540326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540326.